Merial Animal Health has revealed the latest MOO test figures which suggest that the productivity of four out of five UK dairy herds is compromised by high levels of gutworm.
The company says it has been helping dairy farmers to assess the level of gutworm challenge in their herds since 2009 by supporting and promoting MOO tests. The test measures the level of antibody to gutworm (Ostertagia ostertagii) that is present in a bulk milk sample and can determine if the herd has been exposed to low, medium or high challenge.
Data from five years of MOO tests shows that whilst there was a steady reduction in the number of herds with a high challenge between 2009 and 2013, the figure rose in 2014. In 2009, 93% of herds tested high and by 2013 this had fallen to 71% but this rose again to 88% last year.
Merial says that whilst these figures show an overall reduction in challenge since 2009, levels of gutworm across the UK dairy herd are still very high. Those animals affected will suffer from the negative impact of a parasite burden on productivity and fertility.
Between 2009 and 2014 nearly 900 dairy herds across the UK have been tested. During that time several counties had significant numbers of herds with high gutworm challenge results. This included Cheshire (85%), Cornwall (93%), Cumbria (91%), Dyfed (92%), Lancashire (90%), North Yorkshire (83%), Shropshire (86%), Somerset (86%), and Staffordshire (83%).
Sioned Timothy, veterinary adviser for Merial Animal Health, said: “Gutworm can significantly reduce the productivity of the herd. Although adult dairy cows develop immunity to gutworm that makes them resilient to outward clinical signs of infection, it does not prevent them from becoming infected with Ostertagia ostertagi. This parasite burden can reduce milk yield by as much as 2.6 litres per cow per day1”
She continued: “Gutworm may also have a negative impact on fertility. Removing damaging gutworms from dairy cows may improve their fertility and has been linked to reduced calving to conception intervals and improved conception rates2 to levels comparable with animals without a gutworm burden.
"Calving is another key period in the production cycle. Optimising cow and heifer management during this period is critical to the animal’s health and productivity throughout the subsequent lactation. Cows treated for gutworms around the time of calving have been shown to increase their grazing time by almost an hour compared to untreated cows3. Improved appetite and higher dry matter intake helps cows to bridge the energy gap; maximising their production, and reducing the time it takes to get them back into calf4.”
The MOO test figures show that the UK dairy herd continues to be affected by high levels of gutworm challenge. At a time when maximising productivity is vital to dairy business success, farmers should seriously consider testing their herd this autumn and develop a treatment plan with their vet or animal health adviser based on the result.”
MOO tests will be available in autumn 2015. The results of MOO tests are sent to both the farmer and their vet or animal health advisor, to enable them to determine the best course of action and treatment.References1 Reist et al, Effect of eprinomectin treatment on milk yield and quality in dairy cows in South Tyrol, Italy. Veterinary Record 2011 168, 484-487 Vet Rec 2002151:377-3802 McPherson et al. Proceedings of the American Association of Veterinary Parasitologists. 44th Annual Meeting, New Orleans, Louisiana, USA, 1999 Abstr. 28.3 Forbes et al. Behavioural mechanisms underlying production responses in dairy cows treated with eprinomectin. 19th WAAVP Congress 2003, New Orleans4 Sanchez et al. The effect of eprinomectin treatment at calving on reproduction parameters in adult dairy cows in Canada. Preventative Veterinary Medicine 2002 56:165-177
Blue Cross has announced the results from its National Equine Health Survey (NEHS) which show that lameness is three times more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross runs NEHS in May each year, in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by SPILLERS and Zoetis and supported by the UK’s leading equestrian organisations and charities. This year saw a 35% increase in participation compared to 2014, with survey records returned for almost 15,000 horses, ponies, donkeys and mules.
The charity says that whilst of course the horse’s foot is fundamental to soundness and performance, NEHS results have shown consistently that limb lameness, as opposed to foot lameness, is in fact the biggest syndrome affecting horses.
In the latest survey, conducted in May, a total of 18% were recorded as lame. 13.5% of these were recorded as suffering with lameness such as osteoarthritis, also known as degenerative joint disease (13.9% in 2014 and 14.8% in 2013).
Meanwhile foot lameness was recorded in 4.5% of returns, a similar figure to previous years.
Josh Slater from the Royal Veterinary College, who is member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: “NEHS is now producing important evidence that is replacing subjective opinion. While the lameness figures were initially surprising, given that the foot has been generally regarded as the main problem area, the fact that these figures have remained consistent over the past three years gives constructive credibility to the data. Our findings will help owner vigilance with day-to-day healthcare as well as help prioritise on areas for future veterinary education and research.”
The six most notable disease syndromes identified in the 2015 National Equine Health Survey were:
23.2% of horses were reported as being overweight with a Body Condition Score of 3.5-5, continuing the upward trend seen in previous years (16.9% in 2014 and 7.8% in 2013). Next year’s survey will explore links between obesity and the possible associated rise of obesity-related diseases such as equine metabolic syndrome (which was reported in 2.4% of 2015 returns) and laminitis.
The survey also enables participants to report on any health problems not covered in the survey questions, giving them a chance to shape future survey subjects.
Gemma Taylor, Education Officer at Blue Cross explains: “This year 11% of our free text answers mentioned gastric ulcers giving a valuable insight into the prevalence gastric ulcer syndrome in the principally leisure horse NEHS population. As a result we will be adding new questions to the 2016 survey to help us find out more.”
The 2015 NEHS survey results are now available from http://www.bluecross.org.uk/nehs2015results. To register for next year’s survey, visit www.bluecross.org.uk/nehs
Ricochet, one of the UK's leading TV production companies, is on the hunt for dogs with unique personality traits or unusual talents for a forthcoming ITV television documentary.
The hour long programme will look into the characteristics, heritage and personality traits of the most popular dogs in the UK. It'll revolve around dog owners and the extraordinary stories they have about their pets.
Ricochet says it is looking in particular for funny, heart-warming or poignant tales highlighting the bond between dogs and their owners - dogs with unique personality traits or unusual talents, and dogs which have performed amazing feats or changed lives.
If you have an extraordinary dog, or think a client might like to take part, call the Assistant Producer, Beth, on 01273 224800 or email: dogbreeds@ricochet.co.uk
Merial is asking veterinary surgeons to take part in a survey about current understanding of and attitudes to feline vaccination, to be found at: https://www.surveymonkey.com/r/Y5BFY96.
The results will complement Give Them Just What They Need, a new report being produced by the company which will contain relevant published data, owner insight, details of the latest vaccination guidelines and expert commentary.
Vets who complete the survey will be entered into a draw for a £250 Red Letter Day voucher.
Claire Edmunds, product manager at Merial, said: "Our preliminary research has identified that many vets are unaware of the latest developments in feline vaccine technology and the benefits that these developments can offer in terms of important factors such as client compliance.
"This new campaign will gain insight from vets, cat owners and other key opinion leaders to create a report that will ultimately enable practice owners to make better informed decisions about feline vaccinations, communicate more successfully with clients and in turn grow their business.”
The survey will be live until the 13th September.
Animalcare has announced the launch of Identichip Ultra, a new slimline microchip with enhanced read range for smaller species
The new microchip is 1.4mm wide and is inserted with a 15 gauge needle which is 50% slimmer than the needle used with standard microchips. The length of the mini microchip has been increased to 10.3mm to accommodate a longer ferrite rod which boosts the signal to the microchip scanner.
Animalcare says Identichip Ultra has been designed to offer a slimline microchipping solution for small species and breeds with a reduced compromise on read range.
Beverley Campbell, Identichip and Anibase Product Manager said: “We recognised the increasing trend for slimmer microchips and the benefit this offers for small species and breeds. We also know that mini microchips have a reduced read range which could ultimately lead to a microchip not being detected so we wanted to challenge this and bring a solution to the market.
"Identichip Ultra is as slim as the other mini microchips currently being offered but the increased length gives us a read range up to 24% further1. We firmly believe that there is a place for mini microchips in the market and while we have enhanced the read range versus other mini brands we still believe that standard size microchips should be used in larger animals. We would encourage implanters to always choose a microchip size suitable for that particular animal in relation to its size now and when fully grown.”
With compulsory microchipping of dogs due to be introduced in England, Scotland and Wales from April 2016 awareness of microchipping is increasing. However, Animalcare says it still feels there is a lot of education needed to ensure dog owners are prepared for the legislation. For this reason, it has produced a range of promotional materials including leaflets, posters, letter templates and digital stickers.
Identichip Ultra is available in a sterile packed syringe style implanter with a detachable needle for sharps disposal.
For further information speak to your Animalcare Representative.
1Based on a laboratory trial comparing mini microchips (1.4mm x 8.5mm), standard microchips (2.1mm x 12.5mm) and idENTICHIP Ultra (1.4mm x 10.3mm) using three different microchips scanners (RT100-V5, Halo Scanner and idENTICHIP Pocket Reader)
Vetswest, the veterinary support services company, has been acquired by MWI Veterinary Supply, a subsidiary of the US multinational, AmerisourceBergen.
MWI already owns Centaur and VetSpace, and the agreement will allow it to further expand the range of services it offers the animal health profession in the UK.
Jim Cleary, Executive Vice President of AmerisourceBergen and President of MWI Veterinary Supply said: “This partnership reflects our commitment to the success of veterinary practices across the globe. We’re proud to welcome Vetswest to the MWI family as we continue to expand our services in our mission to be the best resource to the animal health profession.”
Vetswest offers group business support services for its 235 member veterinary practices including negotiating manufacturer terms and a proprietary IT system that supports pricing intelligence, inventory information and reporting on purchasing activity. The company also provides access to ancillary services for veterinary surgeons to help manage human resources, continuing professional development, insurance offerings, pension services and other areas which support the growth of member practices.
Vetswest's retiring managing director David Buckley said: “The resources of MWI and AmerisourceBergen will allow us to bring new innovation to the market and additional benefits to Vetswest members. I’m excited about Vetswest’s future under the leadership of Chris Sobey and as part of the MWI and AmerisourceBergen family.”
Chris Sobey, who will become the new managing director of Vetswest following his tenure as Vetswest’s business development director said: “Our goal has always been to improve efficiencies and services for our members through scale and with our new relationship with MWI and AmerisourceBergen, we will be well positioned to further this core mission of our organisation.’’
Zoetis has announced the launch of Versican Plus, a vaccine range for dogs in the UK and throughout Europe.
Versican Plus is the only vaccine to combine DHPPi + L4 in a single injection1, something which Zoetis says is the fruit of several years research and development.
The leptospirosis components of the vaccine have been designed to meet the challenges of both existing and emerging types.
According to the company, Versican Plus is the only tetravalent leptospirosis vaccine to deliver prevention against clinical signs and urinary excretion of established (Icterohaemorragiae and Canicola) and emerging (Bratislava and Grippotyphosa) canine leptospirosis (except Grippotyphosa where prevention of clinical signs occurs but with a reduction in urinary excretion).
Zoetis also highlights the advantage this vaccine brings is in its viral components. Versican Plus utilises a new CPV-2b strain, the most prevalent strain in the UK2, to prevent clinical signs, leucopoenia and viral excretion caused by Parvovirus.
Practices using Versican Plus will have the ability to provide protection at the earliest opportunity, as it has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to Parvovirus, Distemper and Adenovirus at levels equal or higher to those likely to be encountered under field conditions.
As a result Versican Plus can be used from 6 weeks of age with an early onset of immunity being achieved for Parvovirus, Distemper and Adenovirus at 9 weeks. Parainfluenza and Leptospirosis immunity follow shortly thereafter at 12 and 13 weeks respectively.
Following primary vaccinations three to four weeks apart Versican Plus provides 3 years duration of immunity for Parvovirus, Distemper and Adenovirus.
Ned Flaxman, Zoetis UK Companion Animal director said: “Our research and development team has taken many different aspects of vaccination into account to create Versican Plus. As well as offering comprehensive protection in accordance with the current epidemiological situation, the vaccine is also convenient to use. It offers a flexible primary vaccination course with an early finish option from 9 weeks, important for early socialisation reasons.”
For further information, visit www.zoetis.co.uk/versicanplus, contact your Zoetis Account Manager or telephone 0845 300 8034.
References
The RCVS has launched a new animated video to help promote Practice Standards Scheme (PSS) accredited practices to the public, and explain the benefits of the scheme.
Launched in 2005, almost 60% of practices are now part of the PSS, which requires them to submit to a rigorous inspection every four years and meet a stringent standards across a wide range of areas including cleanliness and hygiene, facilities and equipment, staff training and development and customer service. Practices may also be subject to spot-checks between inspections.
Jacqui Molyneux, who heads up the RCVS Practice Standards Group said: “Our new video is a light-hearted explanation of the Practice Standards Scheme, how it can help animal owners decide which practice to go to and reassure them about the standards they can expect to find at an RCVS-accredited practice.”
The College says a similar version of the video will soon be available for RCVS-accredited practices to show to their clients, either on their own websites and social media channels, or in the waiting room.
Jacqui said: “Not only do we want to spread the word about the benefits of the Practice Standards Scheme and suggest animal owners look for the RCVS-accredited practice logo, but we also want to give accredited practices an engaging way of telling their clients about their achievement.
“Gaining RCVS accreditation is not easy, so accredited practices deserve every opportunity to demonstrate to their clients their commitment to supporting high standards of veterinary care. This fun two-minute video should help them do just that.”
Animal owners can search for an RCVS-accredited practice in their area, or elsewhere in the UK, using Find A Vet – the College’s online search tool – at www.findavet.org.uk.
The organisers say that the presentations have been designed to be practical in nature and to provide delegates with useful, take-away information they can apply immediately in practice and that isn’t readily available in textbooks.
Forty-eight presentations will be staged over the two-days across four themed lecture strands: three for vets and a dedicated strand for Veterinary Nurses, although delegates are free to attend any lecture they choose.
The core themes for vets include Orthopaedics, Neurology and Oncology and Soft Tissue Surgery. The Veterinary Nursing strand will cover topics such as Anaesthesia, Arthritis, Cancer, Trauma, Spinal Nursing, Pain Management, Rehabilitation and Nutritional Advice.
Presentations include:
An overarching theme for the festival is ‘One Medicine’, the emerging global concept of combined human and animal medical advancement for the good of all species; Noel Fitzpatrick will give a keynote speech on Saturday 5th September on this subject.
On Sunday 6th September, the closing keynote speech will be delivered by Dr Jane Goodall DBE who will talk about her work as a British Ethologist, conservationist and UN Messenger of Peace and the importance of preserving habitats, species and biodiversity to the continuance of mankind.
A full speaker agenda is available at www.vetfestival.co.uk and attendance at the Festival can be added to delegates’ CPD records.
On Saturday evening, the Festival will host ONE LIVE, a music festival open to delegates, their families and the general public in aid of The Humanimal Trust, a charity inspiring advancement of healthcare initiatives in animals at the same time as humans. Headlining the concert will be Mike and The Mechanics with support from The Hoosiers and Hunter and The Bear.
Tickets for VET Festival cost from £99. There are discounted rates available for Veterinary Nurses and Students and groups of five or more vets or vet nurses can receive a group discount. For more information and to book tickets visit www.vetfestival.co.uk
VetSurgeon.org has 4 free tickets for the full 2 day festival to give away, and a further 12 tickets to the evening concert. We'll be dishing them out randomly amongst those VetSurgeon members who indicate their interest in attending the event by clicking the RSVP button on the entry in the VetSurgeon CPD & Events Diary, here: http://www.vetsurgeon.org/c/veterinary-cpd/events/5.aspx
Animalcare has announced the launch of Clavubactin (amoxicillin/clavulanate) for dogs and cats, presented as 4-way split tablets in three strengths to ensure optimum dosing. The three strengths (Clavubactin 50, 250 and 500) contain 50/12.5, 250/62.5 and 500/125mg of amoxicillin and clavulanic acid respectively. Clavubactin 50mg is licensed for cats and dogs. The 250 and 500mg formulation is licensed for dogs only.
According to the company, the increased combined level of active ingredients, compared to some other clavulanate-amoxicillin products on the market, achieves recommended target weight dosing (doses always kept at 12.5mg/kg), even with animals of greater weight, minimising the risk of underdosing.
The 4-way split tablets are designed to facilitate easy and accurate dosing of all sizes of dogs and cats, from 1kg bodyweight (¼ tablet Clavubactin 50) to 50kg (1 tablet Clavubactin 500) and above.
The tablets come in aluminium blister strips of ten tablets in five packaging presentations (Clavubactin 50 and 250 are available in 100 and 250 tablet packs and Clavubactin 500 in 100 tablets).
Animalcare Product Manager Tony Liepman said "Clavubactin allows for optimum target weight dosing and together with the accuracy enabled by SmartTabs easy 4-way split, this gives peace of mind to both vet and client."
The product is supported by dosage charts and dispensing envelopes (the latter is available on request).
For further information contact Animalcare on 01904 487687, speak to your regional Animalcare representative or visit www.animalcare.co.uk/contact-us.
Virbac has launched Nutribound, a complementary feed to help stimulate eating and drinking in inappetent cats and dogs.
The company says the product has been designed to help animals recovering from surgery or illness and those that are just experiencing a general lack of interest in food or water.
Nutribound is given alongside the pet’s diet but can also be given by tube or syringe if needed.
Claire Lewis, Product Manager, said: "Pets that lose interest in their food can be challenging for owners to deal with - and a pet that is struggling to eat or drink what it needs, especially after illness or surgery is more likely to have a prolonged recovery.
"Nutribound's palatable formulation aims to 'jump-start' normal eating behaviour by stimulating the animal's appetite and increasing its interest in eating and drinking again.
"Nutribound is presented in a handy-sized, take-home bottle and is easy for pet owners to administer. It can be given for up to 14 days or until a return to normal eating and drinking behaviour is observed. We are delighted to add it to our nutritional support range, alongside Nutri-Plus gel, our high energy, nutritional supplement for cats and dogs."
The London Vet Show has announced it will be offering delegates the chance to win a £12,000 trip to Thailand with Worldwide Veterinary Service (WVS) at this year’s event (Olympia Grand, 19th & 20th November).
Delegates will be able to enter the competition by collecting a stamp in their LVS passport from each of the participating sponsors’ stands in the exhibition.
The 13-day working holiday kicks off by flying to Chang Mai in Thailand via Bangkok. The winners will then travel to the Narittaya Resort and Spa where they'll be staying in a private villa with its own pool. Working over the next six days with the WVS team in Chang Mai, they will be supporting an ongoing neutering and vaccination campaign while also training local vets in best practice surgical techniques.
The winners will get the opportunity to explore the temples in the ancient city of Chang Mai and a highlight of the trip will be an overnight visit to the Elephant Nature Park, which is dedicated to providing care and assistance to Thailand’s captive elephant population. The overnight stay will include a full orientation of the park and the elephants and a chance to bathe and swim with the herd in the river and communicate with them.
The winners will also have a chance to go either white water rafting or bamboo rafting.
For further information on the London Vet Show or to register to attend the event visit londonvetshow.co.uk.
CVS has announced that it is to support the Small Animal Veterinary Surveillance Network (SAVSNET), a charity initiative run jointly by the BSAVA and the University of Liverpool to monitor health and illness in companion animals using anonymised data from veterinary practices and laboratories.
The group will be linking its practices, of which there are now more than 290, to SAVSNET through their practice management systems in a rollout that will continue until the end of the year.
Through its research and analysis, SAVSNET aims to monitor disease trends over time; identify populations at risk and monitor treatments and outcomes. It also aims to provide data and improve public awareness of small animal diseases and prevention. One of its projects delivers near-real-time (within 24 hours) practice-based syndromic surveillance based on data received from participating veterinary surgeons, who through a single mouse click, record information at the end of each consultation through their practice management system. The data is automatically sent to SAVSNET for secure storage and analysis. The whole process is designed to avoid any impact on a practices already busy work flow.
Dr Alan Radford, one of SAVSNET’s principal investigators, said: "Reusing electronic health data has a massive potential to improve animal and human health. SAVSNET is one project leading the way in this research and it is great to be working with CVS, with its scale and also its focus on high quality veterinary care.
"Working together, SAVSNET and members of the CVS team can really help understand in a new way the diseases seen by the populations under our care. As a small thank you for participation, practices that take part are provided with a secure on-line portal where they can see free anonymised benchmarking statistics including disease data and antibacterial use. Greater knowledge will enable us to target interventions to those animals most at risk, to identify risk factors for disease and to focus veterinary research efforts."
Marcus Evans, Head of Practice Management Systems at CVS said: "We are very impressed at the projects being carried out by the SAVSNET team and are keen to support its work, particularly as our veterinary teams can do it so quickly and easily through RoboVet, our practice management system. As a large veterinary group, and one that is continuing to grow rapidly, our support will add significant weight to SAVNET's efforts and we are delighted to be contributing to such valuable research."
Researchers at the Animal Health Trust are appealing for information from veterinary surgeons who have seen recent Eosinophilic Keratitis (EK) conditions, an emerging issue in UK equine ophthalmology.
The AHT says that despite the increased awareness of EK worldwide, the aetiopathogenesis of the disease remains poorly understood and probably underdiagnosed. The charity is looking to define the pathogenesis and determine why some horses are particularly susceptible to this condition, in particular looking for epidemiological links, environmental factors and parasitic infestation.
Many of the clinical signs of EK are non-specific and similar to other corneal conditions such as blepharospasm, chemosis, conjunctival hyperaemia, epiphora or perilesional oedema. More specific signs include caseous mucoid discharge and white/yellow plaques often localised in the peripheral cornea. The degree of pain varies and concurrent ulceration is almost always present. Conjunctivitis may also occur in association with the keratitis or as a unique disease entity.
EK can have variable clinical presentations, from a thick caseous accumulation to a more superficial plaque of “ground-glass” appearance. They may present as chronic non-healing ulcers that respond quickly to the use of topical steroids and/or ciclosporin, or present with marked ocular discomfort and require superficial keratectomy to resolve the condition.
Two different corneal locations are classically (though not exclusively) involved in EK, the medial perilimbal cornea, often under the third eyelid, or the lateral perilimbal cornea, which may progress axially towards the central cornea.
The charity is also providing free cytology tests for corneal scrapes to help vets diagnose EK earlier, thereby avoiding secondary complications that can lead to permanent visionary impairment.
If you have seen cases that have either been diagnosed as or that you suspect to be Eosinophilic Keratitis this year, contact Sonia Gonzalez-Medina on 01638 751000 Ext: 1203 or sonia.gonzalez-medina@aht.org.uk.
For more information and to download a copy of the submission form to accompany samples, visit www.aht.org.uk/EKstudy.
The RCVS has published a new video which explains the Professional Development Phase (PDP) and highlights the support it provides for new veterinary graduates as they develop their Year One Competences.
In the video, Victoria Henry MRCVS - who works at Mandeville Veterinary Hospital in Northolt - speaks about how the PDP has helped her move from being a newly-qualified graduate to becoming a confident practitioner. She said: “It’s a massive transition coming out of vet school and going into practice – you suddenly have all the responsibility and it’s all on you. The PDP gives you goalposts to work towards and flags up the areas you don’t have much practice in; it helps you to reflect on what you’ve been doing and assess yourself.”
Jeremy Stewart, the Head Veterinary Surgeon at Mandeville Veterinary Hospital, talks about how the PDP helps employers to support and develop graduates like Victoria by building their confidence and helping them gain the experience they need for practice life.
The video also highlights the support available for graduates undertaking the PDP and features Julian Wells, one of the five Postgraduate Deans who help graduates undertaking the PDP by providing advice on any issues they may encounter, checking their progress and confirming when they have completed it. He also describes how the PDP helps graduates to understand the mentoring role in practice, which they can then provide to new graduates as they progress through their own careers.
Christine Warman, Head of Education at the RCVS, said: “With 859 new UK graduates having just joined the Register, we thought this video would be helpful in setting out why the PDP can be so crucial in helping to build the confidence and experience of new graduates, as well as the fact that it can easily be incorporated into day-to-day work.”
More information about the PDP is available by visiting www.rcvs.org.uk/pdp or by emailing pdp@rcvs.org.uk.
Veterinary surgeons who wish to sign up to the Professional Development Record can do so by visiting www.rcvs-pdr.org.uk
Virbac has launched Neoprinil, an eprinomectin pour-on solution indicated for use against internal and external parasites in cattle, including gut and lungworms, mange mites, sucking and chewing lice, horn flies and warbles.
Neoprinil has a zero-day withdrawal period in milk and can be administered using the company's Farmpack and Flexibag.
The Farmpack is a backpack which holds a Flexibag of Neoprinil solution. The Flexibag is a bag designed to protect medication and preserve it once it has been opened. The two together were awarded the 2014 PharmaPack Award for Innovative Packaging.
Neoprinil offers a one year stability period once it has first been opened and requires no special conditions for storage. It is presented in 2.5L, 4.5l and 8l pack sizes.
Product Manager for Large Animals Brigitte Goasduf MRCVS said: "A high worm burden can have adverse effects on the herd's productivity and performance and so it is advisable to ensure infected animals are treated as part of a Herd Health Plan. Eprinomectin is a tried and trusted parasiticide and studies confirm that it can have a positive impact on both milk production and on weight gain. Its zero day withdrawal period is a major benefit for dairy farmers.
"With the launch first of Deltanil and, now, Neoprinil, we are reinforcing our commitment to work with veterinary surgeons and farmers to understand the everyday challenges they face and to provide practical, effective solutions. We offer a comprehensive parasiticide range with a dispensing system that sets a new standard for convenience and ease of use."
Ceva Animal Health has launched Libeo, a new four-way break, palatable furosemide for the management of heart failure in dogs.
According to the company, furosemide - a diuretic - is the most frequently used treatment for the management of heart failure because it helps reduce pulmonary oedema and its quick onset of action is associated with a noticeable reduction in clinical signs.
However, Ceva highlights the fact that long-term under or over-dosing can have profound health implications for the patient, and says that current recommendations are to reduce the dose to the minimum effective dose as soon as the animal is stable and only increase it if required due to deterioration in heart function.
Ceva says that unlike other furosemides, Libeo has been designed solely for the veterinary market - specifically to facilitate easy and accurate dosing.
The four-way break tablet is available in a traditional 40mg tablet size as well as a unique 10mg size for small patients. The clover-shaped tablet is chicken-flavoured, designed to make it easier for owners to dose their pets and help improve long-term owner compliance. Each box of Libeo contains 120 blister-packed tablets, removing the need for someone to have to count out tablets.
Rob McLintock MRCVS, Companion Animal Business Unit Manager at Ceva Animal Health said: “87% of vets in the UK believe that the dose of furosemide given to pets by their owners is adversely affected by how difficult it is to split the tablets1. This is especially likely to affect pets whose owners are less dextrous or have difficulties using their hands. Libeo is both easy to administer and effective, thereby improving owner compliance and the long term health and welfare of their pets.”
Reference
Lincolnshire veterinary surgeon David Bull MRCVS has won a Vet Futures ‘Headlines of tomorrow’ competition with his entry: ‘Vets and medics collaborate to prevent human and animal obesity’.
The competition was held at BSAVA Congress in April where Vet Futures-themed fortune cookies contained a message asking those attending ‘What future headline do you want to see?’ and providing a weblink to enter the competition.
David, a joint partner at Vets4Pets in Lincoln South and an Advanced Practitioner in General Small Animal Surgery, said: "The headline was inspired by topical issues, having ‘One Health’ in mind and the issue of obesity in our patients, as well as the general human population. I feel that these are some of the big issues of our time, especially that of obesity which has been linked to so many other diseases and is essentially a self-induced problem.
“We see so many overweight cats, dogs and rabbits on a daily basis. It seems to be becoming a more common problem, as well as seemingly more accepted in society. This is to the extent that we have some clients that come in worried because they have been told that their dog is too thin, when in actual fact they are in an ideal body condition and are being compared to overweight pets which have become perceived as normal.”
Some of the other topics raised in the competition include the veterinary profession taking the lead in tackling ‘superbugs’, veterinary surgeons topping job satisfaction and wellbeing polls and the profession taking a leading role in One Health and medical advancements.
Scientists from the Animal Health Trust, the Wellcome Trust Sanger Institute and the University of St. Andrews have pinpointed the genes which allow the bacteria responsible for strangles to thrive, thereby paving the way for the development of a vaccine.
In the study, which the researchers say was the largest of its kind, 224 samples of Streptococcus equi (S. equi) were procured from horses around the globe to try and find a common bacterial ancestor from which modern strains would have developed. Despite the disease first being described in 1251, the researchers were surprised at the genetic similarity of the samples and identified a total population replacement at the 19th or early 20th century. This corresponds to a period when horses from around the world were brought together in global conflicts including World War I, where an estimated eight million horses died on the battlefield.
Dr Simon Harris from the Wellcome Trust Sanger Institute said: “The mobilisation and mixing of horses in conflicts such as WWI provided perfect conditions for S. equi to thrive. This combined with high mortality rates among the horses and their replacement with young susceptible horses could explain what we see around the world today".
While loss of diversity could be considered detrimental to bacterial populations, S. equi still infects more than 20,000 horses in the UK alone each year. Its success, researchers believe, is due to its ability to persist in some horses for years after they have recovered from strangles, where the bug can evolve to evade the horse’s immune system.
Dr Andrew Waller, Head of Bacteriology at the Animal Health Trust said: “The data we have gathered in this study has enabled us to pinpoint the genes that help the bacteria to persist, spread and thrive in the horse population. This research provides an unprecedented opportunity to reduce the impact of and prevent strangles in future generations of horses.”
The AHT says that the ability of S. equi to adapt to living in a persistent state within its host and still infect new horses mirrors the situation with HIV and the bacteria that causes tuberculosis in humans. Dr Matthew Holden from the Wellcome Trust Sanger Institute and the University of St Andrews said: “Unravelling the complex population dynamics of S. equi sheds new light on the balancing act between acute and persistent infection that is going on in many pathogens. Not only does this collection of whole-genome sequences for S. equi offer hope for an effective strangles vaccine, it also provides us with a useful model for understanding persistent infection in humans.”
Bayer Animal Health has announced changes to the product indications for Baytril 50mg/ml and 100mg/ml Solutions for Injection, which both contain enrofloxacin.
Baytril 50mg/ml and 100mg/ml Solutions for Injection, now have licensed indications for the treatment of sheep and goats.
Baytril 50mg/ml and 100mg/ml* Solutions for Injection are now licensed for the treatment of acute mycoplasma-associated arthritis due to enrofloxacin- susceptible strains of Mycoplasma bovis in cattle (*in cattle less than 2 years old.)
For the treatment of acute severe mastitis caused by enrofloxacin - susceptible strains ofEscherichia coli in cattle, the second injection of Baytril 100 mg/ml Solution for Injection may now be given subcutaneously, 24 hours after the first dose administered by intravenous injection. In this case, the withdrawal period following subcutaneous injection should be applied.
For more information, refer to the product data sheets at www.noahcompendium.co.uk and SPCs or speak to your local Bayer Animal Health representative.
The RCVS reports that its alternative dispute resolution (ADR) trial is now nearing completion with over two-thirds of its target number of cases either resolved or in process.
The year-long trial, which began in November 2014, aims to gather the evidence needed to develop a permanent scheme which would provide a way of adjudicating on concerns raised about a veterinary surgeon that do not meet the RCVS threshold of serious professional misconduct.
The aim of the trial, which is administered by the independent, not-for-profit Ombudsman Services, is to make determinations on around 100 cases in order to gather information about types of concern, time taken to resolve disputes, recommendations and how likely each party is to accept recommendations. As of this week some 72 cases have been referred to the trial scheme, with final decisions made in relation to 54 of these cases.
RCVS CEO Nick Stace was responsible for pushing forward the trial believing that “what is good for the consumer is good for the profession”. The College also says it brings it into line with a European Union Directive on alternative dispute resolution which, while not legally binding, specifies that regulators and other ‘competent authorities’ should have consumer redress systems in place.
Nick said: “The majority of cases are either being determined in the veterinary surgeon’s favour or finding that they need take no further action in order to resolve the dispute. Where recommendations have been made in favour of the client, the suggested remedies have generally been for a small goodwill payment to be made.
“However, the trial has not been without some frustrations so far. The fact that participation in the trial is entirely voluntary has meant that, in many cases, members of the profession have chosen not to take part.
“With this in mind, it is very important to stress the benefits of the trial to the profession – chiefly that many of the vets who chose to take part have had their actions exonerated by Ombudsman Services in a way that a concern being closed by our Professional Conduct Department does not. For clients, where a vet does have a case to answer, it gives them the chance to seek recompense without having to resort to legal action.
“Regardless of which way the decision goes in any of these cases, participating in the trial can bring these often long-standing and burdensome disputes to a close.”
The trial will continue to run until the end of October and a full report and recommendations will be presented to RCVS Council at its meeting on Thursday 5 November 2015. Full details of the trial and its parameters can be found at www.rcvs.org.uk/adr
Elanco Animal Health has launched an updated Atopica Comfort Club, a support initiative for veterinary professionals treating either canine atopic dermatitis or feline allergic dermatitis cases with Atopica.
The Atopica Comfort Club loyalty scheme now has a new website which enables all members of the practice team to see the cases being managed and the offers available for new and existing users post diagnosis. The initiative provides veterinary practices with a free of charge Atopica redemption scheme through both induction and maintenance periods.
Elanco says the new website will also enable veterinary practices to view and redeem offers instantly, receive reminders about offers and updates together with emails to confirm offers have been redeemed and the products despatched.
Alice Laurens, DVM MRCVS, Dermatology Marketing Manager at Elanco Animal Health, said: “The Comfort Club loyalty scheme embraces a multi-modal approach and ensures better comfort is provided to Atopica patients with options to offer a flea product, shampoo, essential fatty acids and an adapted diet.”
To support the new Atopica Comfort Club loyalty program, Elanco has also produced a ‘practice log book’ to enable vets to record details on each case which can then be entered onto the Comfort Club website.
For further information, or to book a lunch and learn meeting, please contact your local Elanco Animal Health key account manager or email elancoCAH.uk@elanco.com.
CVS has announced its acquisition of the Dovecote Veterinary Hospital, a general and referral practice based in Castle Donington near Derby.
The Dovecote offers a range of referral services including digital X-ray, MRI and CT scanning capability. Its directors, Andrew Robinson, a European RCVS Recognised Specialist in Small Animal Surgery, and Alison Robinson have been appointed joint Clinical Directors.
Dovecote joins ChesterGates Veterinary Specialists in Chester, Norfolk-based Grove Referrals and St David's Veterinary Group in Devon in CVS' referral practice portfolio. The Group also has a new veterinary hospital - Lumbry Park Veterinary Specialists - under construction at Alton, Hampshire; opening in October 2015.
In addition to the Dovecote, CVS has announced the acquisition of further first opinion practices based in Yorkshire and Wales. They are:
Simon Innes, Chief Executive of CVS, said: "These latest acquisitions show continued progress towards our goal of building a strong presence throughout all sectors of veterinary practice. It is a particularly exciting time for our referral team and we are delighted to welcome the team from Dovecote, as well as the other new practices which have joined us recently."
Langford Veterinary Services, a fully owned subsidiary of the University of Bristol, has announced the opening of a new standing equine magnetic resonance imaging (MRI) facility at the university's equine centre.
The equine MRI facility completes the diagnostic imaging facilities in the School, which include a 16-slice CT scanner for small animals and standing horses, digital radiography, high-resolution fluoroscopy, diagnostic ultrasound, echocardiography and scintigraphy with a high-resolution 1.5 tesla MRI scanner, available seven days a week.
Evita Busschers, Senior Teaching Fellow and orthopaedic surgeon in the equine centre, said: “We are very grateful to the Trustees of the Alborada Trust and the Langford Trust who have provided generous support for the MRI facility. The new imaging facility will enable us to provide an even better and more complete service for our equine patients and completes the diagnostic imaging facilities available at the centre.
“Equine MRI offers the ability to image soft tissue structures and identify soft tissue injuries that cannot be demonstrated with other diagnostic imaging modalities and therefore has major additional value in providing a diagnosis and prognosis in lameness evaluations.”
Miles Littlewort, a trustee from the Alborada Trust added: “Donating the money is the easy bit but ensuring that it has been used where it should be and that it has made the necessary difference is much more challenging. We are so pleased to have had the opportunity to support the Langford Trust and their work to improve animal health and welfare. We are delighted to have attended the opening, to meet the clinicians who will use the magnificent facility and to learn about the clinical research which gives all veterinary surgeons evidence-based information to enhance diagnosis and treatment for all patients.”
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk